NIKKEI 225
38,556.87 -298.50 (-0.77%) HANG SENG
18,477.01 -344.15 (-1.83%) CRUDE OIL
79.28 -0.55 (-0.69%) GOLD FUTURES
2,336.90 -19.60 (-0.83%) DOW
38,441.54 -411.32 (-1.06%) Bitcoin GBP
53,067.30 -802.88 (-1.49%)
AZN Jan 2025 42.500 call
| Previous close | 25.05 |
| Open | 25.05 |
| Bid | 21.45 |
| Ask | 22.95 |
| Strike | 42.50 |
| Expiry date | 2025-01-17 |
| Day's range | 25.05 - 25.05 |
| Contract range | N/A |
| Volume | |
| Open interest | 20 |
BenzingaAmgen Secures FDA Nod For Rare-Disease Treatment Biosimilar Based On AstraZeneca's Drug
Tuesday, the FDA approved Amgen Inc (NASDAQ:AMGN) Bkemv (eculizumab-aeeb) as the first interchangeable biosimilar to AstraZeneca Plc’s (NASDAQ:AZN) Soliris (eculizumab) to treat certain rare diseases. Bkemv is approved for the following treatment indications, which are also currently approved for Soliris: The treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis. The treatment of patients with atypical hemolytic uremic syndrome (aHUS) to inhibit complement-medi
ZacksAstraZeneca (AZN) Falls on Failure to Meet NSCLC Study OS Goal
AstraZeneca's (AZN) shares decline as it fails to achieve statistically significant overall survival data in a late-stage NSCLC study on Dato-DXd compared with docetaxel.
Fool.co.ukWhere is the UK stock market headed for the rest of 2024?
I've been searching high and low to uncover insightful opinions from professionals about where the UK stock market is headed in 2024. The post Where is the UK stock market headed for the rest of 2024? appeared first on The Motley Fool UK.
